Blog

A Carr & Ferrell attorney gave a guest presentation on AMP v. Myriad at Professor Larry Lasky’s Entrepreneurship in Biotechnology class at UC Berkeley’s Haas School of Business.  The presentation included an overview of the case, and explored how this ruling could impact the future of gene patents.

Last spring, a federal district court sent shockwaves through the life science and legal communities when it struck down several of Myriad Genetics’ patent claims regarding genes linked to ovarian and breast cancer.  In a move that could shape the future of gene patenting if upheld, the court ruled that DNA sequences are not, in and of themselves, patentable subject matter.

Myriad has appealed that decision to the U.S. Court of Appeals for the Federal Circuit, which will hear oral arguments in April 2011.

See the slide presentation, AMP v. USPTO.